Skip to content

Idexx Laboratories IDXX CAG — Goodwill

Other segment segments

Water segment revenue
$18.41M+1.6%
LPD
$15.12M+12.1%

Similar metrics at other companies

Liquidity Services logo
LQDTCAG — Goodwill
$21.45M+0.6%
Tetra Tech logo
TTEKCIG — Goodwill
$1.31B+4.0%
Wolverine World Wide logo
WWWActive Group — Goodwill
$319.8M+0.7%
Netgear logo
NTGRConsumer — Goodwill
$0
Mesa Laboratories logo
MLABClinical Genomics — Goodwill
$17.12M+1.2%
Digital Turbine logo
APPSAGP — Goodwill
$142.88M+0.9%

Other financials

Income statement

See full
Revenue$1.1B+14.3%
Gross profit$722.7M+15.9%
Operating income$362.6M+14.5%
Net income$278.4M+14.7%
EPS (diluted)$3.47+17.2%

Balance sheet

See full
Cash & equivalents$200.5M+22.3%
Total debt$575.5M-22.2%
Total equity$1.6B+7.5%
Total assets$3.4B+5.3%

Cash flow

See full
Operating cash flow$266.2M+11.9%
CapEx$32.0M+6.5%
Free cash flow$234.3M+12.7%

Valuation

See full
Market cap$43.5B+2.0%
Enterprise value$43.88B+1.7%
P/E39.7×-3.6×
P/S9.8×-0.8×

Profitability

See full
Gross margin62.1%+0.8pp
Operating margin31.6%+2.5pp
Net margin24.6%+1.9pp
FCF margin24.4%+2.8pp

Returns & leverage

See full
Return on equity72.9%+13.6pp
Debt / equity0.4×-0.1×
Current ratio1.1×0.0×

Where this comes from

Reported directly by Idexx Laboratories in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Idexx Laboratories’s 10-K, filed February 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Idexx Laboratories's cag — goodwill.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Idexx Laboratories's CAG — goodwill?
Idexx Laboratories (IDXX) reported CAG — goodwill of $374.45M in Q4 2025.
How has Idexx Laboratories's CAG — goodwill changed year-over-year?
Idexx Laboratories's CAG — goodwill increased by 2.0% year-over-year, from $366.98M to $374.45M.
What does CAG — goodwill mean?
This represents the intangible asset value recorded when the Companion Animal Group segment acquires another business for a price exceeding the fair market value of its identifiable net assets. It reflects the premium paid for brand reputation, customer relationships, and proprietary technology within the veterinary diagnostics market. This balance is subject to periodic impairment testing to ensure the carrying value remains supported by future cash flows.